Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 3 The comparisons of women with epilepsy surgically-treated (WWE-S) (n=13) versus medication-treated only (WWE-MO) (n=34)

From: Hippocampal sclerosis in women with temporal lobe epilepsy: seizure and pregnancy outcomes

Variable

WWE-MO

(n=34)

WWE-S

(n=13)

P-value

Age at pregnancy mean (SD)

25.4 (3.0)

26.3 (3.1)

0.92

Educational years >12 (n, %)

15 (44.1%)

4 (30.8%)

0.82

Duration of epilepsy (years, median,IQR)

9.0 (6.0–10.0)

10.0 (7.5–14.0)

0.26

Seizure freedom in the pre-conceptional years (n,%)

1 (2.9%)

8 (61.5%)

0.001*

FBTCS frequency (none) in the preconceptional year (n,%)

22 (64.7%)

11 (84.6%)

0.030*

FIAS frequency (monthly) in the preconceptional year

15 (44.1%)

2 (15.4%)

0.003*

Levetiracetam use before pregnancy (n, %)

10 (29.4%)

4 (30.8%)

0.99

Seizure exacerbation during pregnancy (n, %)

17 (50.0%)

2 (15.4%)

0.031*

Seizure freedom during pregnancy (n, %)

6 (17.6%)

10 (76.9%)

<0.001*

Seizures in the postpartum week (n, %)

6 (17.6%)

1 (7.7%)

0.69

Polytherapy during pregnancy (n, %)

9 (26.5%)

6 (46.2%)

0.37

Levetiracetam use during pregnancy (n, %)

13 (38.2%)

5 (38.4%)

0.99

ASM adherence (n, %)

21 (61.8%)

8 (88.9%)a

0.30

Induced delivery (n, %)

9 (26.5%)

0 (0.0%)

0.047*

Cesarean section (n, %)

19 (55.9%)

8 (61.5%)

0.21

  1. Abbreviations: WWE-MO Medication-only treated women with epilepsy, WWE-S Surgically treated women with epilepsy
  2. *P-value